Search and analyze individual stocks with comprehensive metrics
Vivo Bio Tech Ltd
Fundamental Score
Vivo Bio Tech Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of VIVOBIOT across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (39.41%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Attractive Valuation (P/E: 16.64 vs Industry: 51.82)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
10 factors identified
Below-Average Return on Equity (5.68%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (9.04%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Profit Decline Concern (-83.37%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Limited Growth History (-3.35% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities. Assess future growth catalysts.
Weak Earnings Growth (-8.66% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Stagnant Profit Growth (-3.27% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity. Assess transformation initiatives.
Weak Interest Coverage (1.88x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-28.72 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints. Assess capital allocation strategy.
Small Market Cap
Observation: Higher investment risk due to limited size.
Analysis: Small-cap stocks typically carry higher volatility and liquidity risks.
Loading Peer Comparison
Finding companies in the Biotechnology sector...
Financial Statements
Comprehensive financial data for Vivo Bio Tech Ltd
About VIVOBIOT
Business Overview
Vivo Bio Tech Limited provides drug development and discovery services to pharmaceutical and biotech companies worldwide. The company offers services in the areas of in vivo and in vitro toxicity studies, pharmacological investigations, pharmacokinetic and toxic kinetic studies, genotoxicity screening, and analytical services. It also supplies SPF lab animals; breeds and distributes rodent models; and offers custom rodent models, and stem cell products, as well as lab animal diets. In addition, the company provides regulatory and non-regulatory IND preclinical development services; screening and evaluating molecules for various pharmacological properties; and designs and develops of syngeneic / xenograft models for evaluation of anti-cancer agents' evaluation. The company was formerly known as Sunshine Factors & Exports Limited and changed its name to Vivo Bio Tech Limited in September 2002. Vivo Bio Tech Limited was incorporated in 1987 and is based in Hyderabad, India.
Company Details
Key Leadership
VIVOBIOT Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Vivo Bio Tech Ltd (VIVOBIOT)?
As of 20 Jan 2026, 11:12 am IST, Vivo Bio Tech Ltd (VIVOBIOT) is currently trading at ₹28.95. The stock has a market capitalization of ₹68.05 (Cr).
Is VIVOBIOT share price Overvalued or Undervalued?
VIVOBIOT is currently trading at a P/E ratio of 16.64x, compared to the industry average of 51.82x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Vivo Bio Tech Ltd share price?
Key factors influencing VIVOBIOT's price include its quarterly earnings growth (Sales Growth: 8.89%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Vivo Bio Tech Ltd a good stock for long-term investment?
Vivo Bio Tech Ltd shows a 5-year Profit Growth of -3.27% and an ROE of 5.68%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.58 before investing.
How does Vivo Bio Tech Ltd compare with its industry peers?
Vivo Bio Tech Ltd competes with major peers in the Biotechnology. Investors should compare VIVOBIOT's P/E of 16.64x and ROE of 5.68% against the industry averages to determine its competitive standing.
What is the P/E ratio of VIVOBIOT and what does it mean?
VIVOBIOT has a P/E ratio of 16.64x compared to the industry average of 51.82x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹17 for every ₹1 of annual earnings.
How is VIVOBIOT performing according to Bull Run's analysis?
VIVOBIOT has a Bull Run fundamental score of 16/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does VIVOBIOT belong to?
VIVOBIOT operates in the Biotechnology industry. This classification helps understand the competitive landscape and sector-specific trends affecting Vivo Bio Tech Ltd.
What is Return on Equity (ROE) and why is it important for VIVOBIOT?
VIVOBIOT has an ROE of 5.68%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Vivo Bio Tech Ltd generates profits from shareholders' equity.
How is VIVOBIOT's debt-to-equity ratio and what does it indicate?
VIVOBIOT has a debt-to-equity ratio of 0.58, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is VIVOBIOT's dividend yield and is it a good dividend stock?
VIVOBIOT offers a dividend yield of 0.00%, which means you receive ₹0.00 annual dividend for every ₹100 invested.
How has VIVOBIOT grown over the past 5 years?
VIVOBIOT has achieved 5-year growth rates of: Sales Growth -3.35%, Profit Growth -3.27%, and EPS Growth -8.66%.
What is the promoter holding in VIVOBIOT and why does it matter?
Promoters hold 35.16% of VIVOBIOT shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is VIVOBIOT's market capitalization category?
VIVOBIOT has a market capitalization of ₹68 crores, placing it in the Small-cap category.
How volatile is VIVOBIOT stock?
VIVOBIOT has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for VIVOBIOT?
VIVOBIOT has a 52-week high of ₹N/A and low of ₹N/A.
What is VIVOBIOT's operating profit margin trend?
VIVOBIOT has a 5-year average Operating Profit Margin (OPM) of 39.41%, indicating the company's operational efficiency.
How is VIVOBIOT's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 8.89% and YoY Profit Growth of -83.37%.
What is the institutional holding pattern in VIVOBIOT?
VIVOBIOT has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the stock.